首页> 美国卫生研究院文献>Journal of the Royal Society of Medicine >Safety and efficacy of nifedipine 20 mg tablets in hypertension using electronic data collection in general practice.
【2h】

Safety and efficacy of nifedipine 20 mg tablets in hypertension using electronic data collection in general practice.

机译:一般情况下使用电子数据收集硝苯地平20毫克片剂在高血压中的安全性和有效性。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Electronic data collection was used in this open study to survey the safety and efficacy of nifedipine when used in the treatment of 3972 patients with mild to moderate essential hypertension. The safety and efficacy results are presented and discussed as well as the advantages, disadvantages and reliability of electronic data collection. The validity of data collected electronically has not previously been tested, such data having been assumed to be reliable. The pattern of adverse events reported in this study is compared with the pattern of reports to the Committee on Safety of Medicine (CSM), to Bayer UK and in a large paper-based study of nifedipine, in order to test these assumptions. Reported adverse medical events pre-treatment, prior to entry to the study and noted at visit 1, were compared with reports during treatment in the study at visits 2 and 3. The expected incidence of flushing and headache was seen which diminished with continued treatment. Reductions were seen in dyspnoea and impotence. Ankle oedema was observed and was not reduced by time alone. After one month of treatment with nifedipine 20 mg tablets twice daily, 66.5% of patients had a sitting phase V diastolic blood pressure of 90 mmHg or below and 79% of 95 mmHg or below.
机译:在这项开放研究中,电子数据收集用于调查硝苯地平用于治疗3972例轻度至中度原发性高血压患者的安全性和有效性。介绍并讨论了安全性和有效性结果,以及电子数据收集的优缺点和可靠性。以前尚未测试过以电子方式收集的数据的有效性,这些数据被认为是可靠的。为了检验这些假设,将本研究报告的不良事件的模式与药物安全委员会(CSM),拜耳英国和硝苯地平的大型纸质研究的模式进行了比较。将进入研究前且在研究1中注意到的治疗前报告的不良医学事件与研究在研究2和3的治疗期间的报告进行比较。看到潮红和头痛的预期发生率随着继续治疗而降低。呼吸困难和阳imp见减轻。观察到脚踝浮肿,仅靠时间并不能减轻。每天两次使用硝苯地平20 mg片治疗一个月后,有66.5%的患者坐姿V期舒张压为90 mmHg或以下,而79%的患者为95 mmHg或以下。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号